research use only

Xanomeline AChR agonist

Cat.No.E4714

Xanomeline(LY-246708) is a selective agonist of muscarinic type 1(M(1) receptor and muscarinic type 4 receptor(M(4). It increases neuronal excitability and inhibits behaviors induced by D-amphetamine and (-)-apomorphine.
Jump to

Quality Control

Batch: Purity: 99.54%
99.54

Solubility

In vitro
Batch:

DMSO : 56 mg/mL (198.99 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 56 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 281.42 Formula

C14H23N3OS

Storage (From the date of receipt)
CAS No. 131986-45-3 Download SDF Storage of Stock Solutions

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC50/Ki
M1 mAChR
M4 mAChR
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-07)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07686263 NOT_YET_RECRUITING
Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
2026-09-03 PHASE3
NCT07084831 NOT_YET_RECRUITING
Schizophrenia; Psychosis; Cognitive Impairment
European Group for Research In Schizophrenia
2027-01-01 PHASE3
NCT07011732 RECRUITING
Alzheimer Disease
Bristol-Myers Squibb
2025-07-10 PHASE3
NCT07011745 RECRUITING
Alzheimer's Disease
Bristol-Myers Squibb
2025-07-16 PHASE3
NCT07221877 RECRUITING
Schizophrenia
Bristol-Myers Squibb
2026-01-20 PHASE4
NCT07140913 RECRUITING
Mania; Bipolar Disorder
Bristol-Myers Squibb
2025-10-08 PHASE3

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map